尼莫司汀对复发恶性胶质瘤化疗的临床观察  

Clinical Observation of Chemotherapy with ACNU in Recurrent Glioma

作　　者：许杰阳 孙跃文[1] 娄淼[2] 刘竞辉[2] 冯富强[2] 冀培刚[2] 李宝福[2] 李毅[2] 高国栋[2] 王樑[2] 

机构地区：[1]第四军医大学临床医学系学员旅八队,陕西西安710038 [2]第四军医大学唐都医院神经外科胶质瘤研究治疗中心,陕西西安710038

出　　处：《现代生物医学进展》2014年第29期5720-5722,共3页Progress in Modern Biomedicine

基　　金：卫生部医药科技发展计划研究课题(w2012fz104);陕西省自然科学基金项目(2012JQ4003)

摘　　要：目的:探讨尼莫司汀在复发胶质瘤化疗的疗效。方法:回顾性分析接受尼莫司汀化疗的13例复发胶质瘤患者的临床治疗效果、生存时间及不良反应。结果:所有患者均接受超过3个周期的化学治疗,平均完成4.6个化疗周期。随访时间5-26个月,平均随访时间16个月。3个月无进展生存率53.8%;6个月无进展生存率30.8%;12月无进展生存率23.1%。2例出现Ⅲ度骨髓抑制,其余不良反应包括恶心呕吐(6例)和疲倦乏力(9例),经积极治疗后均好转。结论:尼莫司汀为主的化疗方案是复发胶质瘤化疗的有效手段之一,可以显著地延长患者的生命,并不伴有严重的并发症,特别是针对前期进行过TMZ化疗的病例,具有价格低廉,疗效相当的优点,是替莫唑胺治疗之外很好的选择。Objective： To investigate the effect of chemotherapy with ACNU on recurrent glioma. Methods： 13 patients with recurrent glioma treated with ACNU were retrospectivly analyzed for therapeutic effects, survival time and adverse reactions. Results： All patients received more than three cycles of chemotherapy, with an average of 4.6 cycles. They were averagely followed-up for 16 months （5-26 months）. Progression-free survival rates of 3 months, 6 months and 12 months were 53.8%, 30.8% and 23.1%, respectively. Two patients had bone marrow suppression during the course. The other adverse reactions included nausea and vomiting （6 cases） and fatigue （9 cas^s）, and improved after active treatment. Conclusion： Chemotherapy with ACNU is one of the effective methods for recurrent glioma, which can significantly extend the lifetime of patients without serious complications. Patients who received TMZ-based chemotherapy will benefit more from ACNU for its low price and comparable effect, thus, ACNU is a good choice for non-TMZ therapy.

关 键 词：尼莫司汀 胶质瘤 复发 化疗 

分 类 号：R739.41[医药卫生—肿瘤]